Xuankuo Xu
About Xuankuo Xu
Xuankuo Xu is the Director of Biologics Downstream Development at Bristol Myers Squibb in Devens, MA, with extensive experience in biologics development and process implementation.
Title
Xuankuo Xu serves as the Director of Biologics Downstream Development at Bristol Myers Squibb, based in Devens, MA.
Career at Bristol Myers Squibb
Xuankuo Xu has had a progressive career at Bristol Myers Squibb, dating back to 2008. He began as Scientist I in East Syracuse, NY, before transitioning through multiple roles, including Scientist II, Senior Scientist I, Senior Scientist II, Principal Scientist/Group Leader, and Senior Principal Scientist/Associate Director in Devens, MA. He held each position for varying durations, with his roles focusing on upstream and downstream biological processes, as well as leading and guiding new technology implementations.
Education and Expertise
Xuankuo Xu earned his Ph.D. in Chemical Engineering from the University of Delaware between 2002 and 2008. Prior to this, he completed both his Master of Science (M.S.) in Chemical Engineering and Bachelor of Science (B.S.) in Chemical Engineering Equipment & Machinery (Process Control & Equipment) at Tianjin University. His advanced education has provided him with a strong foundation in chemical engineering principles, which he has effectively applied to his roles in biologics development and downstream processing.
Professional Contributions
Xuankuo Xu chairs the Manufacturing Strategy Forum at Bristol Myers Squibb, responsible for technology transfer and process implementation. He is a member of the Biologics Downstream Commercialization Committee, focusing on pipeline and platform alignment, and represents Global Downstream in the Biologics IP Review and Advisory Committee. In addition, Xuankuo oversees academic collaborations, leads focus groups, and spearheads technical initiatives aimed at evolving the Downstream Platform.
Publications and Patent
Xuankuo Xu has made significant contributions to scientific literature and intellectual property. In 2022, he published a paper on 'Behavior of Weakly Adsorbing Impurities in Flow-Through Ion-Exchange Chromatography' in the Journal of Chromatography A. He also authored papers on virus clearance validation, virus inactivation, and productivity improvement in cell culture processes in Biotechnol Bioeng and Biotechnol J in 2021. Additionally, he has a patent application for 'High-Affinity Supramolecular Polymers for Binding-Triggered Antibody Precipitation and Purification'.